Kazuhiko Uchiyama1, Nobuaki Yagi1,2, Katsura Mizushima1, Yasuki Higashimura1, Yasuko Hirai1, Tetsuya Okayama1, Naohisa Yoshida1, Kazuhiro Katada1, Kazuhiro Kamada1, Osamu Handa1, Takeshi Ishikawa1, Tomohisa Takagi1, Hideyuki Konishi1, Yoshiaki Kuriu3, Masayoshi Nakanishi3, Eigo Otsuji3, Yoshito Itoh1, Yuji Naito4,5. 1. Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho Hirokoji Kawaramachi Kamigyo-ku, Kyoto, 602-8566, Japan. 2. Department of Gastroenterology, Murakami Memorial Hospital, Asahi University, 3-23 Hashimotocho Gifu-city, Gifu, 500-8523, Japan. 3. Department of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine, 465 Kajiicho Hirokoji Kawaramachi Kamigyo-ku, Kyoto, 602-8566, Japan. 4. Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho Hirokoji Kawaramachi Kamigyo-ku, Kyoto, 602-8566, Japan. ynaito@koto.kpu-m.ac.jp. 5. Department of Endoscopy and Ultrasound Medicine, Kyoto Prefectural University of Medicine, 465 Kajiicho Hirokoji Kawaramachi Kamigyo-ku, Kyoto, 602-8566, Japan. ynaito@koto.kpu-m.ac.jp.
Abstract
BACKGROUND: Although colorectal cancer (CRC) is one of the most common causes of cancer mortality, early-stage detection improves survival rates dramatically. Because cancer impacts important metabolic pathways, the alteration of metabolite levels as a potential biomarker of early-stage cancer has been the focus of many studies. Here, we used CE-TOFMS, a novel and promising method with small injection volume and high resolution, to separate and detect ionic compounds based on the different migration rates of charged metabolites in order to detect metabolic biomarkers in patients with CRC. METHODS: A total of 56 patients with CRC (n = 14 each of Stages I-IV), 60 healthy controls, and 59 patients with colonic adenoma were included in this study. Metabolome analysis was conducted by CE-TOFMS on serum samples of patients and controls using the Advanced Scan package (Human Metabolome Technologies). RESULTS: We obtained 334 metabolites in the serum, of which 139 were identified as known substances. Among these 139 known metabolites, 16 were correlated with CRC stage by upregulation and 44 by downregulation, with benzoic acid (r = -0.649, t = 11.653, p = 6.07599E-24), octanoic acid (r = 0.557, t = 9.183, p = 7.9557E-17), decanoic acid (r = 0.539, t = 8.749, p = 1.24352E-15), and histidine (r = -0.513, t = 8.194, p = 3.90224E-14) exhibiting significant correlation. CONCLUSIONS: To the best of our knowledge, this is the first report to determine the correlation between serum metabolites and CRC stage using CE-TOFMS. Our results show that benzoic acid exhibited excellent diagnostic power and could potentially serve as a novel disease biomarker for CRC diagnosis.
BACKGROUND: Although colorectal cancer (CRC) is one of the most common causes of cancer mortality, early-stage detection improves survival rates dramatically. Because cancer impacts important metabolic pathways, the alteration of metabolite levels as a potential biomarker of early-stage cancer has been the focus of many studies. Here, we used CE-TOFMS, a novel and promising method with small injection volume and high resolution, to separate and detect ionic compounds based on the different migration rates of charged metabolites in order to detect metabolic biomarkers in patients with CRC. METHODS: A total of 56 patients with CRC (n = 14 each of Stages I-IV), 60 healthy controls, and 59 patients with colonic adenoma were included in this study. Metabolome analysis was conducted by CE-TOFMS on serum samples of patients and controls using the Advanced Scan package (Human Metabolome Technologies). RESULTS: We obtained 334 metabolites in the serum, of which 139 were identified as known substances. Among these 139 known metabolites, 16 were correlated with CRC stage by upregulation and 44 by downregulation, with benzoic acid (r = -0.649, t = 11.653, p = 6.07599E-24), octanoic acid (r = 0.557, t = 9.183, p = 7.9557E-17), decanoic acid (r = 0.539, t = 8.749, p = 1.24352E-15), and histidine (r = -0.513, t = 8.194, p = 3.90224E-14) exhibiting significant correlation. CONCLUSIONS: To the best of our knowledge, this is the first report to determine the correlation between serum metabolites and CRC stage using CE-TOFMS. Our results show that benzoic acid exhibited excellent diagnostic power and could potentially serve as a novel disease biomarker for CRC diagnosis.
Authors: Neil J Shimwell; Wenbin Wei; Sue Wilson; Michael J O Wakelam; Tariq Ismail; Tariq Iqbal; Philip J Johnson; Ashley Martin; Douglas G Ward Journal: Cancer Biomark Date: 2010 Impact factor: 4.388
Authors: Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan Journal: Nature Date: 2009-02-12 Impact factor: 49.962
Authors: Niels Lech Pedersen; Mathias Mertz Petersen; Jon J Ladd; Paul D Lampe; Robert S Bresalier; Gerard J Davis; Christina Demuth; Sarah Ø Jensen; Claus L Andersen; Linnea Ferm; Ib J Christensen; Hans J Nielsen Journal: Clin Chim Acta Date: 2020-04-06 Impact factor: 3.786
Authors: Tabassum A Khan; Tyler J Loftus; Amanda C Filiberto; Tezcan Ozrazgat-Baslanti; Matthew M Ruppert; Sabyasachi Bandyopadhyay; Evagelia C Laiakis; Dean J Arnaoutakis; Azra Bihorac Journal: Ann Surg Date: 2021-02-01 Impact factor: 13.787
Authors: Nikos Papadimitriou; Marc J Gunter; Neil Murphy; Audrey Gicquiau; David Achaintre; Stefanie Brezina; Tanja Gumpenberger; Andreas Baierl; Jennifer Ose; Anne J M R Geijsen; Eline H van Roekel; Andrea Gsur; Biljana Gigic; Nina Habermann; Cornelia M Ulrich; Ellen Kampman; Matty P Weijenberg; Per Magne Ueland; Rudolf Kaaks; Verena Katzke; Vittorio Krogh; Bas Bueno-de-Mesquita; Eva Ardanaz; Ruth C Travis; Matthias B Schulze; Maria-José Sánchez; Sandra M Colorado-Yohar; Elisabete Weiderpass; Augustin Scalbert; Pekka Keski-Rahkonen Journal: Int J Cancer Date: 2021-07-12 Impact factor: 7.396